Ajinomoto AminoScience to Speak and Exhibit at TIDES 2011 in Boston

Company to Highlight its Innovative AjiPhaseLiquid Phase Peptide Synthesis Service

RALEIGH, N.C.--(BUSINESS WIRE)--May 17, 2011 - Ajinomoto AminoScience LLC (AAS) today announced it will be presenting and exhibiting at the 2011 Oligonucleotide and Peptide® Technology and Product Development Conference (TIDES®), May 22-25 in Boston, Massachusetts. Ajinomoto's Dr. Daisuke Takahashi will be leading a technology workshop and participating in a panel discussion. In addition, the company will showcase its AjiPhase™ liquid phase peptide synthesis service at booth #218.

TIDES® is the most comprehensive industry event and is the place to meet all the important players in oligonucleotide and peptide therapeutics, diagnostic development and manufacturing, as well as raw material and equipment supply and discovery.

Ajinomoto's AjiPhase™, which debuted during the TIDES® 2010 Innovation Showcase, is an innovative peptide synthesis and manufacturing technology that enables the synthesis of complex peptides that have previously proven difficult to synthesize by traditional solid phase synthesis. The innovative anchor technology allows hydrophobic, long and complex peptides to be produced high crude purity and overall yield. In addition, AjiPhase™ allows the use of a single peptide synthesis methodology throughout therapeutic peptide development, negating the need to transition between solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS) methodologies as volume requirements increase.

Daisuke Takahashi will present a technology workshop entitled “AjiPhase™ - A Development of Liquid Phase Peptide Synthesis” on Tuesday, May 24 at 12:15 pm. He will also be speaking as part of the panel discussion “The PolyPeptide Toolbox - a Holistic Approach to Improvement” on Tuesday, May 24 at 4:00 pm.

For more information on AjiPhase™, please visit www.ajiphase.com.

About Ajinomoto AminoScience, LLC

Ajinomoto is the leading supplier of pharmaceutical and research-grade amino acids in the US and throughout the world. Leveraging its unrivaled foundation of more than 50 years of experience identifying, refining, and marketing amino acids, Ajinomoto AminoScience, LLC (AAS) continues to innovate and set new industry standards for manufacturing and related services within the fermentation and expression fields. Building on its legacy, AAS has transitioned the same level of quality and performance into new core competencies in the areas of recombinant protein expression and peptide synthesis. These new processes enable pharmaceutical and biotech companies to develop high-quality products that were previously thought to be too complicated or expensive to produce. The CorynexTM Recombinant Protein Expression System is a streamlined, more efficient process to produce complex human proteins for pharmaceutical use using a specially-developed gram-positive bacterium, Corynebacterium glutamicum. The AjiPhase™ service enables the use of a single peptide synthesis methodology throughout therapeutic peptide development as peptide requirements increase. Ajinomoto AminoScience, LLC is a part of Ajinomoto USA Inc., a wholly-owned subsidiary of Ajinomoto Co., Inc. For more information on AAS and its products and services, please refer to http://www.ajiaminoscience.com/Default.aspx##.

 

 

Contact: Crossroads Public Relations for Ajinomoto AminoScience
Molly Thompson, 919-821-2822
mobile: 919-605-0022
aji@crossroadspr.com

 

 

Posted: May 2011

View comments

Hide
(web1)